Spanish caffeine supplier Natraceutical reported a turnover of €14.3 million for the nine months to end of September, with margins of more than 44 per cent.
The company, which has this year filed for three different patents for polyphenol and dietary fibre-based food ingredients, reported EBITDA of €2.9 million and a net profit of €1.4 million for the nine month period.
Federico Gregori, Natraceutical's financial director, said the results were as predicted.
"Looking to the start of the new quarter, we'll see the figures grow until they reach that forecast for the year-end, as we already have an order-portfolio which will guarantee this turnover," he added.
Natraceutical, the biotechnology division of the Natra Group, expects to close this financial year with a turnover of €21 million, and profits of around €2 million. It is investing heavily innutraceuticals to boost growth potential and margins.
Listed on Spain's new market since the end of last year, Natraceutical reported a 78 per cent rise in turnover in the first half of the year, to €9.5 million for the six months.
The company also announced that its subsidiary Extratos Naturais da Amazônia (EXNAMA) has recently certified its Quality Management System, based on the requirements of the Standard NBR ISO 9001:2000.
